Estrella Immunopharma, Inc.
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
ESLA | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 5858 HORTON STREET, SUITE 370, 94608 EMERYVILLE
- Website:
- https://www.estrellabio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing transformative T-cell therapies to treat cancer and autoimmune diseases. The company leverages its proprietary ARTEMIS® T-cell platform, a next-generation immunotherapy designed to enhance the ability of T-cells to recognize and kill cancer cells. Its development pipeline includes candidates targeting proteins such as CD19 and CD22 for indications including blood cancers, like B-cell non-Hodgkin's lymphoma, and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Estrella Immunopharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Estrella Immunopharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Estrella Immunopharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
